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Previous clinical studies focused primarily on the clinical characteristics and surgical management of pterygia and, because of this, the pathogenesis of pterygia remains incompletely understood. However, considerable progress in this area has been achieved, providing additional insight into this complex disease. This recent evidence implicates antiapoptotic mechanisms, immunological mechanisms, cytokines, growth factors, extracellular matrix (ECM) modulators, genetic factors, viral infections, and other possible causative factors (figure 1). 1 2 Limited investigation regarding differences in pathogenesis of primary and recurrent pterygia has been performed. We attempt to summarise many of these recent discoveries concerning the pathogenesis of pterygia as well as to describe reported differences between primary and recurrent pterygia.
DISCUSSION Oxidative stress
UV-B light has been attributed as a major cause of pterygia. Patients with increased UV-B exposure, such as those living close to the equator, or patients with sunlight-related conditions such as basal cell carcinoma, polymorphous light eruption and xeroderma pigmentosum have an increased risk of pterygia formation. 3 UV-B exposure causes oxidative stress, leading to upregulation of many potential mediators of pterygium growth. 8-Hydroxydeoxyguanosine, a marker commonly used to identify oxidative damage to DNA, has been found in pterygia tissue in several studies. 4e6 Human 8-oxoguanine glycosylase 1 (hOGG1), the enzyme that metabolises 8-hydroxydeoxyguanosine, has also been noted to be upregulated in these tissues. 5 In addition, certain polymorphisms in human 8-oxoguanine glycosylase 1 have been shown to increase the risk of pterygia. 7 Oxidative stress yields increased reactive oxygen and nitrogen species, leading to DNA damage, lipid peroxidation and alterations in protein structure. Glutathione S-transferase M1 null genotype, which confers increased sensitivity to UV light, is also found at increased frequency in younger patients with a pterygium. 8 UV-B exposure and resultant oxidative stress likely play a primary role in pterygia pathogenesis.
Cell cycle regulation
The cell cycle, specifically defective regulation of apoptosis, likely plays a significant role in pterygia formation and growth. Impression cytology specimens of pterygia show squamous metaplasia and fewer apoptotic markers. 9 Staining of TUNEL and bax, two apoptotic markers, is only significant in the epithelial basal layer of pterygia, but normal conjunctival tissue shows full thickness staining. An antiapoptotic protein bcl-2, which counteracts with the pro-apoptotic protein bax found in both pterygia and conjunctiva, has been found in pterygia epithelium but not in conjunctiva. 10 An increase in survivin, a member of the inhibitor of apoptosis protein family, has been associated with pterygia. Maxia et al 11 hypothesised that UV-B exposure and resultant oxidative stress leads to increased survivin levels, yielding resistance to UV-induced apoptosis and a hyperproliferative state.
The p53 tumour suppressor has been extensively investigated for its role in pterygia development. p53 acts as a checkpoint by preventing proliferation and subsequently inducing apoptosis if DNA mutations exist. In several studies, an increased level of p53 confined to pterygia basal epithelium has been noted. 12e14 Despite this increase, it was hypothesised that a p53 mutation does not allow the protein to function normally, yielding pterygia growth. 15e17 Other studies have reported variability in the presence of p53 mutations (15.7e38.1%) and the absence of wild-type p53 in pterygia, suggesting that p53 mutations may not be required for pterygia formation.
16e18 UV irradiation has also been shown to stabilise p53, which could help explain increased detected p53 levels in pterygia. 19 Later studies have found no increase in p53 levels with pterygia, arguing against the significance of the role of p53 mutations in pterygia development and suggesting that a resistance to p53 may be involved. 18 20e22 These variable results could be due to methodological differences or may reflect a normal response to UV insult and altered cell turnover. Because mutations in p53 are not found in most of the pterygia, the finding of overexpression of p53 would indicate a mutation in the p53 pathway, such as a protein that regulates p53 activity or a protein required to signal growth stimulation or apoptosis, may be the initial step in pterygia formation.
Other cell cycle regulators have been studied including p16, p27, p63 (a member of the p53 gene family), cyclin D1, Ki67, proliferating cell nuclear antigen, K-RAS and Ku70.
2 23e26 p16, p27, p63, cyclin D1, Ki67, proliferating cell nuclear antigen and K-RAS are all proteins that provide checkpoints for cell division and thus regulate proliferation. Ku70 is a DNA double-strand break repair protein, and genetic polymorphism for this gene has been associated with pterygia. 27 Hypermethylation of the tumour suppressor gene p16 promoter, which correlates with decreased p16 expression, and mutations in the K-RAS oncogene have also been reported. 24 28 Loss of regulation of these proteins allows pterygia to grow unchecked. An increase in telomerase activity, which prevents telomere shortening during cell replication and prolongs cell life, has also been reported in pterygia epithelium. 29 At this time, there is still controversy over these cell cycle proteins with regard to their relationship to pterygia.
Loss of heterozygosity (LOH) and microsatellite instability (MI) are characteristics of transformed cells, and LOH for tumour suppressor genes may increase the risk of pterygia formation. 30e32 Detorakis et al have found that, with pterygia, LOH is common (most often at 9p (48%), followed by 17q (42%)), but MI of DNA was uncommon. LOH was not detected in phenotypically normal conjunctival tissue obtained from a solar-protected site beneath the upper eyelid, demonstrating these genetic alterations are likely due to UV exposure. 30 However, a recent study has not found evidence of LOH or MI in pterygia samples. 33 These inconsistent findings may reflect methodological differences or variation in the frequency of LOH and MI between study populations.
Inflammatory mediators
Regardless of the inciting agent, inflammatory mediators appear to be associated with pterygia development and growth. After UV-B exposure, chemokines, cytokines, and growth factors are induced, which lead to the influx of inflammatory cells and neovascularisation. Interleukin (IL)-6, IL-8, and tumour necrosis factor-a are increased in pterygia and after UV-B exposure. 34e36 An increase in IL-1 also occurs after UV-B exposure, which contributes to upregulation of other inflammatory mediators and matrix metalloproteinases and potentially to pterygia pathogenesis. 1 Cyclooxygenase-2 is overexpressed in pterygia, yielding a further increase in prostaglandin products and inflammatory cascades. 37 An increase in phospholipase D, which is involved in inflammation and cellular differentiation, was also found in pterygia. 38 Inflammatory mediators are likely secondarily elevated with pterygia and not the primary cause of formation.
Immunologic mechanisms
Although current evidence is not definitive, immunological mechanisms likely contribute to the development of pterygia. Pterygia samples have increased levels of cell signalling and adhesion molecules, such as vascular cellular adhesion molecule-1, intercellular adhesion molecule-1 and aberrant expression of human leucocyte antigen-DR. 39 40 Other signalling molecules, including E-cadherin and b-catenin, are upregulated and concentrated in the heads of pterygia. 41 Increased b-catenin has been shown to trigger certain cell cycle proteins and matrix metalloproteinases. 42 An increase in mast cells, lymphocytes, plasma cells, dendritic cells and CD4+ and CD8+ T cells in pterygia samples has also been documented. 39 40 43 Stromal infiltrates in pterygia of T cells with an increased helper to suppressor ratio and abnormal deposits of immunoglobulins E and I have been described. 44 45 A subsequent study screened pterygial gene expression compared to normal conjunctival tissue, finding significant increase in macrophage inflammatory protein-4. 46 Type I, III and IV hypersensitivity reactions may Figure 1 Pathogenesis of pterygium.
also be related to pterygia development. 44 45 These immunological mechanisms have been associated with pterygia, but it is unclear if they are involved in pathogenesis or if they are only secondarily expressed after pterygia formation.
Growth factors
Other signalling mechanisms such as growth factors have been studied for their role in pterygia development. These signals include heparin-binding epidermal growth factor (HB-EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor, platelet-derived growth factor, connective tissue growth factor, transforming growth factor-b, insulin-like growth factor binding protein-2 and stem cell factor.
35 47e54 These factors have been shown to be elevated in pterygia, playing an important role in cell proliferation, inflammation, connective tissue remodelling and angiogenesis. HB-EGF also induces cell migration of both pterygia epithelium and fibroblasts.
1 Previous studies found that b-FGF, VEGF and HB-EGF are upregulated after UV-B exposure. 34 55 56 A decrease in pigment epitheliumderived factor (PEDF) and insulin-like growth factor binding protein-3 levels in pterygia have also been documented. 48 51 PEDF acts as an angiogenic inhibitor; therefore, decreased levels likely contribute to angiogenic stimulation and pterygia formation and progression. 48 VEGF-460C polymorphism has been implicated with earlier pterygia formation in female patients. 57 Increased expression of neurotrophic factors, including ciliary neurotrophic factor (CNTF), substance P, neutrotrophin-4 and neurotrophin-5, has also been shown in pterygial tissues. 58 Variability in pterygia mutations may result in the differing patterns of growth factor expression, and this may explain the wide variation in growth seen clinically.
Angiogenic stimulation
Inflammation induces angiogenic pathways, resulting in neovascularisation and contributing to pterygia development and growth. Markers for vascular endothelial cells such as CD31 + are increased in pterygia. 59 Many angiogenic factors are elevated in pterygia including VEGF, thrombospondin-1 and substance P.
59e61 Elevation in both tear and plasma levels of these factors are found in patients with pterygia, which increases the activity of ETS-1 transcription factor, directly promoting angiogenic activity. 62 In addition to increased VEGF, the active proliferative status of pterygia vasculature was demonstrated with intense staining for integrin molecules P-and E-selectin. 1 Inducible nitric oxide synthase is also coexpressed with VEGF, yielding increased nitric oxide and contributing further to angiogenesis and inflammation. 63 Another study of pterygia found an increase in erythropoietin receptor without a corresponding increase in erythropoietin, suggesting an erythropoietin-independent erythropoietin receptor signalling pathway stimulating cellular proliferation and angiogenesis. 64 Angiogenic stimulation due to UV-B exposure or inflammatory pathways is likely a secondary phenomenon, contributing to pterygia growth.
Extracellular matrix modulation
UV-B light and inflammatory mediators also increase the expression of matrix metalloproteinases, important molecules in ECM remodelling. Alterations due to ECM remodelling may contribute to limbal degeneration and subsequent pterygia formation. Mutations in elastin and tropoelastin, components of connective tissue, have been reported in association with pterygia.
65e68 Elastin and fibronectin levels have also been found to be increased in pterygia. 46 69 The fibrovascular tissue of pterygia has been noted to have myofibroblasts, which has been confirmed with immunostaining. 70 Recently, bone marrowderived progenitor cells, both haematopoietic and mesenchymal, have been proposed to contribute to pterygia fibrovascular stroma. 2 71 72 This is supported by the increase in CD34+ progenitor cells in the blood of pterygia patients. 71 One recent review also discussed the possibility of epithelial mesenchymal transition, a process in which epithelial cells take on characteristics of mesenchymal cells as the origins of pterygia fibroblasts.
2
Matrix metalloproteinases (MMPs), including MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin 1), MMP-7 (matrilysin) and MMP-9 (gelatinase B), are elevated in pterygia, particularly in the advancing heads.
173e77 Expression of MMP-8 (neutrophil collagenase) and membrane-type MMP (MMP-14 and MMP-15) have also been reported. 68 In fact, in cultured pterygia fibroblasts, the addition of inflammatory signals increases the expression of MMP-1 and MMP-3. 76 77 MMP-1 promoter polymorphism and LOH at 11q22.23, precisely the site of the MMP-1 locus, recently have been associated with pterygia.
1 MMP-7 is also involved in angiogenesis, demonstrated by the elevation of active MMP-7 specifically in pterygia vasculature. 78 MMP activity is controlled by endogenous inhibitors such as a2-macroglobulin and tissue inhibitors of metalloproteinases (TIMPs). Disregulation of MMP versus TIMP activity has been associated with pterygia. 1 67 Interestingly, staining for TIMP often parallels MMP and could be responsible for the slow but progressive growth of pterygia. 1 Matrix metalloproteinase expression plays a role in the migration and growth of pterygia but is not likely a prerequisite to formation. Variation in expression of MMP may explain differences in growth of pterygia seen clinically.
Cholesterol metabolism modification
Peiretti et al noted an association between pterygia development and modifications in cholesterol metabolism. Increased levels of hydroxyl-methylglutaryl-coenzyme A-reductase and lowdensity lipoprotein receptor were found, and the authors suggested that this could be involved in stimulation of fibroblast proliferation. 79 80 In fact, certain lipid metabolism-altering drugs decreased the proliferation of pterygia fibroblasts. 81 This association may serve as a future therapeutic target to prevent pterygia development and growth.
Viruses
Viruses have been hypothesised to promote proliferation of tissue or induce mutations in DNA that encourage tumorigenesis. Previous studies found that human papillomavirus (HPV) and herpes simplex virus were found in several biopsies from pterygia but not from any normal conjunctival tissue. 82 83 However, subsequent studies did not corroborate their findings. 12 84 85 Another study demonstrated geographic variability of HPV in pterygia with all samples collected from Italy testing positive for HPV but only 5 of 24 Ecuadorean pterygia. 86 The discrepancies between previous studies may be related to this geographic variability in viral infection rates. Therefore, viruses may play a role in pterygia development though the importance of this mechanism remains unproven. 87 Because most pterygia are not associated with viruses, viruses may increase susceptibility but are not required for pterygia pathogenesis.
among patients with pterygia. Some previous studies showed an increased risk of pterygia in patients with a positive family history, but no definite pattern of inheritance, was observed. 55 Other reports suggest the pattern of inheritance of familial pterygia to be autosomal dominant with incomplete penetrance. 2 Previous reports of families with numerous affected individuals often at an early age including one set of monozygotic twins provide additional evidence for genetic factors influencing predisposition to pterygia.
1 Despite these anecdotal reports, limited evidence from twin studies, migration studies or segregation analysis studies supports a hereditary relationship, and familial clusters may only arise because of a common environment or occupation. 3 
Primary versus recurrent pterygia
Although the pathogenesis of pterygia is still in question, little is known regarding differences between primary and recurrent pterygia. The few studies that made a distinction between primary and recurrent pterygia determined that p53 is unlikely to play a role, finding equivalent p53 levels between primary and recurrent cases. 14 16 One study found that pterygia initially positive for p53 became negative in subsequent recurrence, suggesting that p53 accumulation was not associated with recurrence. 88 K-RAS mutations correlate with postoperative recurrence and are more prevalent in younger patients. 28 Levels of VEGF, basic fibroblast growth factor, and substance P were significantly higher in recurrent pterygia, but the opposite relationship was seen with PEDF. 35 47 55 A decrease in L-3-phosphoserine phosphatase homologue and increases in periostin and TIMP-2 have been found in recurrent pterygia. 89 A greater increase in CD34 cells in recurrent versus primary pterygia has also been reported. 47 LOH at 9q31e33 was seen more often in recurrent pterygia and was postulated to be a possible predictor of recurrence. 30 A downregulation or absence of PAX-6, the universal master control gene for eye morphogenesis, has also been associated with abnormal epithelial differentiation with recurrent pterygia. 90 One study showed increased proliferation of the fibrovascular layer in recurrent pterygia, but others reported no such differences. 91 92 An association between pterygia recurrence and the presence of both HPV and herpes simplex virus has been reported. 83 Although further study is needed in this area, these findings suggest significant differences in the pathogenesis of primary and recurrent pterygia.
CONCLUSION
Pterygium is a common ocular surface disease associated with chronic UV exposure. UV exposure leads to oxidative stress which causes genetic damage and stimulates inflammatory pathways, leading to a hyperproliferative state. 1 A focal alteration of limbal stem cells in pterygia is also a well-established concept and is key to understanding pterygia pathogenesis. 93 This focal alteration and the predominant interpalpebral location have been attributed to the focussing of reflected solar radiation (albedo) on the corneal limbus. 94 Recent research has used ultraviolet fluorescence photography to analyse patterns of cellular activity to further understand pterygia pathogenesis. 95 96 Previous literature also implicates involvement of antiapoptotic mechanisms, immunological mechanisms, cytokines, growth factors, ECM modulators, genetic factors, viral infections and other possible causative factors (figure 1). 1 2 Although significant research has been performed in an attempt to further characterise pterygia pathogenesis, the specific stimulus leading directly to pterygia formation and growth remains a mystery.
The contributions of inflammatory mediators, immunological mechanisms, growth factors, angiogenic stimulation and ECM modulation are likely secondary in nature after actual pterygia pathogenesis. ECM modulation may be involved early in the invasive mechanism of pterygia. p53 mutations and viruses may increase the likelihood of pterygia formation but do not seem to be a prerequisite to pterygia formation. UV-B-related DNA mutations with resultant loss of cell cycle regulation are likely key to pterygia pathogenesis. Hereditary factors may increase the likelihood of genetic mutations and predispose these individuals to pterygia formation. The pathogenesis and growth of pterygia are complex in nature, and further research in this area may allow alternative effective targeted therapeutic strategies for this condition.
Previous literature regarding differences in the pathophysiology of primary and recurrent pterygia is limited. Contrasting histopathologic and clinical findings between primary and recurrent pterygia are well described, suggesting that further differences in mediators driving their growth may be present. 93 Further research will continue to elucidate these differences and provide insight into these clinical entities.
